Clinical Trial Update: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of retigabine IR as adjunctive therapy for adults with partial-onset seizures has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Retigabine (ezogabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2018-02-26